How to Cite

Megrelishvili, T., kvitashvili, M., Mikadze, I., Pachkoria, E., & Kipiani, N. (2023). EFFICACY OF PAXLOVIDE IN THE TREATMENT OF COVID-19 PATIENTS WITH DIABETES TYPE 2. COLLECTION OF SCIENTIFIC WORKS OF TBILISI STATE MEDICAL UNIVERSITY, 56, 92–95. Retrieved from https://journals.4science.ge/index.php/CSW/article/view/2286


The Covid-19 pandemic is the most important global health problem of the 21st century. Diabetes Mellitus is considered one of the risk factors for worsening the course of covid-19 infection and the development of possible life-threatening complications. The aim of the study was to evaluate the effectiveness of Paxlovide in mild and moderate Covid-19 patients with diabetes, analysis of study results, and their consideration in clinical practice. The use of Paxlovide in treatment at the early stage of the disease – during the first 5 days is associated with rapid reduction: of the pathological symptoms, in the progression to a severe form, and in the risk of mortality in elderly patients. It’s important that observation of the patients took place during the dominance of the Omicron variant of the covid-infection in our country. Thus, it can be assumed that Paxlovid is effective against the omicron variant of covid-infection.



Ronza Najjar-Debbiny, Naomi Gronich, Gabriel Weber, Johad Khoury, Maisam Amar, Nili Stein, Lee Hilary Goldstein, and Walid Saliba. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2022 Jun 2 : ciac443. Published online 2022 Jun 2. doi: 10.1093/cid/ciac443.

World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. 2022. Available at: https://covid19.who.int/. Accessed 30 April 2022.

Deborah E. Malden, DPhil 1,2 ; Vennis Hong, MS 2 ; Bruno J. Lewin, MD 2,3 ; Bradley K. Ackerson, MD 2 ; Marc Lipsitch,DPhil 4,5 ; Joseph A. Lewnard, PhD 6 ; Sara Y. Tartof, PhD 2,3.

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022. Centers for Disease Control and Preven-

tion. Weekly / June 24, 2022 / 71(25);830-833.

Karolina Akinosoglou, Georgios Schinas and Charalambos Gogos. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. MDPI. Depart-

ment of Internal Medicine, Medical School, University of Patras, 26504 Rio, Greece * Correspondence:akin@upatras.gr; Tel.: +30-697-776-2897.

Anne L. Peters. Does covid-19 raise the risk for diabetes? MAY 17, 2022. www.medscape.com.

Diabetes Double Risk of Death From Covid-19; EastWest Divide? Mariene Busko, May 13, 2022.www.medscape.com.


Download data is not yet available.